Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome by Jansen, M.J.J.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
This full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/14935
 
 
 
Please be advised that this information was generated on 2014-11-11 and may be subject to
change.
Laboratory Investigations
Inflammatory cytokines in an experimental model 
for the multiple organ dysfunction syndrome
Monique J. J. M. Jansen; Thijs Hendriks, PhD; Maria T. E. Vogels, PhD; Jos W. M. van der Meer, MD, PhD; 
R. Jan A. Goris, MD, PhD
Objective: To investigate the alterations in circulating pro- 
inflammatory cytokines and cytokine production by peritoneal 
macrophages during the development of multiple organ dysfunc­
tion syndrome.
Design: Prospective, controlled laboratory study on zymosan- 
induced generalized inflammation in mice. Single intraperitoneal 
administration of zymosan induces, over a 12-day period, a triphasic 
illness in mice: the third phase, from day 6 onward, resembles 
multiple organ dysfunction syndrome.
Setting: Animal research laboratory.
Subjects: C57BL/6CRW mice received a single intraperitoneal 
dose of zymosan on day 0, and standard numbers of animals were 
killed at different time points up until day 12.
Measurements and Main Results: Plasma concentrations of 
interleukin (IL)-1a and IL-1 p, IL-6, and tumor necrosis factor (TNF)- 
a  were measured from 3 hrs to 12 days after administration of 
zymosan. At the same time points, both lipopolysaccharide-
stimulated and unstimulated production of these cytokines by 
peritoneal macrophages were measured in vitro.
Plasma TNF and IL-6 concentrations transiently increased dur­
ing the first 24 hrs after administration of zymosan. After 8 days, a 
prominent peak of biologically inactive TNF was observed. Both 
unstimulated and lipopolysaccharide-stimulated cytokine produc­
tion by peritoneal cells showed profound changes during the 
experimental period.
Conclusions: These findings seem to confirm our hypothesis 
that the macrophages are in a continuously activated state and 
altered in their function, when the animals develop multiple organ 
dysfunction syndrome. Further studies are needed to elucidate 
what happens with these cytokines at the tissue level, to better 
understand the pathophysiology of multiple organ dysfunction 
syndrome. (Crit Care Med 1996; 24:1196-1202)
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f all patients now dying in 
the intensive care unit or 
in a surgical department, 
50% to 60% die because of 
multiple organ dysfunction syndrome. 
Multiple organ dysfunction syndrome 
(1) is a cumulative sequence of pro­
gressive deterioration of function oc­
curring in several organ systems, fre­
quently seen after shock, in multiple 
trauma patients suffering from sepsis, 
severe burn wounds, or pancreatitis 
(2-7). This syndrome generally starts 
with lung failure and is followed by 
failure of the liver, gut, and kidneys, 
organs not necessarily directly in­
volved in the primary disease. Fur­
thermore, between the primary dis­
ease and the development of multiple 
organ dysfunction syndrome lies a
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period of days to weeks. Therefore, it 
is thought that endogenous and exog­
enous circulating factors mediate this 
multiple organ dysfunction syndrome
(8 , 9).
Macrophages are multifunctional 
cells that play a central role in host 
defense (10, 11). Not only do they pro­
cess and present antigens to lympho­
cytes and exert antimicrobial activi­
ties, they also act as secretory cells 
during an inflammatory response, pro­
ducing a variety of cytokines, such as 
interleukin (IL)-l, tumor necrosis fac­
tor (TNF)-a, and IL-6 (10, 12-15).
It is assumed that a continuously 
activated state of the macrophage can 
result in an abundant production of 
inflammatory mediators. Such an in­
flammatory response can occur sys- 
temically as a reaction to serious in­
fections, and may contribute to the 
development of multiple organ dys­
function syndrome (16-19). It has been 
suggested that TNF exerts an impor­
tant role in this respect (20, 21). How­
ever, the pathogenic pathways to
multiple organ dysfunction syndrome 
remain to be elucidated. The patterns 
of cytokines like TNF, IL-1 and IL-6 in 
the circulation, as well as the capacity 
of macrophages to produce these sub­
stances during the development of 
multiple organ dysfunction syndrome, 
is not known because of variability in 
the clinical situation of multiple or­
gan dysfunction syndrome patients 
(variety of underlying illness, medica­
tion), and because tissue macrophages 
are not easy to obtain in patients.
In our laboratory, an animal model 
for multiple organ dysfunction syn­
drome has been developed (9, 22-24). 
Rodents that receive intraperitoneal 
zymosan display zymosan-induced gen­
eralized inflammation and develop an 
illness, which ultimately leads to a 
clinical picture resembling multiple 
organ dysfunction syndrome. To gather 
insight into the possible role of vari­
ous cytokines in its pathogenesis, we 
measured the patterns of circulating 
IL-la and IL-ip, IL-6 , and TNF-a in
the subsequent phases of zymosan-
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induced generalized inflammation in 
mice. In addition, we investigated the 
capacity of peritoneal macrophages, 
harvested in different phases of the 
model, to produce these cytokines.
MATERIALS AND METHODS
Animals. Experiments were per­
formed using inbred C57BL/6 male 
mice (Charles River, WIGA, Germany), 
6 to 8 wks old, weighing 20 to 25 g. 
The animals had free access to acidi­
fied water and standard chow (Hope 
Farms, Woerden, The Netherlands). 
The day/night cycle was 12/12. Before 
use, the animals were allowed to ac­
climatize for 1 wk. Three days before 
the actual experiment started, the ani­
mals were customized to daily han­
dling to reduce stress during the ex­
periment. The study protocol was 
approved by the Animal Ethics Re­
view Committee of the Faculty of Medi­
cine, University of Nijmegen.
Zymosan-Induced Generalized In­
flammation. The animal model of zy­
mosan-induced multiple organ dys­
function syndrome has been described 
previously (9, 22-24). Mice were given 
an aseptic intraperitoneal injection 
with zymosan (Sigma Chemical, St. 
Louis, MO) suspended at 25 mg/mL, 
in paraffin oil (60 to 80 milliPascal). 
The dose was 1 mg/g body weight. Zy­
mosan A, a carbohydrate-rich cell wall 
preparation derived from the yeast 
Saccharomyces cereuisiae was steril­
ized by y-radiation (5 kiloGray). The 
particles were suspended in sterile 
paraffin oil, and high-frequency vibra­
tion during 1 hr was done to obtain a 
homogeneous suspension. After soni- 
cation, in batches of <6 mL, the sus­
pension was sterilized again in a 
waterbath at 100°C for 80 mins. All 
suspensions were freshly made before 
use.
Body weight, body temperature, and 
behavior of the animals injected with 
the zymosan suspension were moni­
tored for 12 days. At different time 
points after the zymosan injection, 
groups of animals (n = 14, unless oth­
erwise indicated) were killed to obtain 
samples of blood, peritoneal cells, and 
tissues for analysis.
Collection of Plasma and Peritoneal 
Cells. Mice were anesthetized with 
ether and a blood sample was collected 
individually by means of eye extrac­
tion in capillary whole blood collectors.
K.,-ethylenediaminetetraacetic acid- 
plasma was separated by centrifuga­
tion at 1500 g for 10 mins at 4°C, 
pooled (plasma of seven animals was 
pooled; at each time point, there were 
two pools available), aliquoted, and 
stored at -70°C until assayed. Prior 
experiments showed that pooling of 
plasma did not affect the outcome of 
cytokine measurements (unpublished 
information). After blood collection, the 
animals were killed by cervical dislo­
cation, and 5 mL of ice-cold sterile 
phosphate buffered saline containing
0.38% citrate was injected into the 
peritoneal cavity. After gently mas­
saging, the cell suspension was re­
drawn under aseptic conditions. The 
cells were washed twice in cold phos­
phate buffered saline and resuspended 
in RPMI 1640 (Dutch modification), 
containing 0.1 M of sodium-pyruvate,
2 mM of L-glutamine (Gibco, Paisley, 
UK), and 0.05 mg/mL of gentamicin 
sulfate at a concentration of 1 x 106 
viable cells/mL. Cell viability was de­
termined by trypan blue exclusion.
Cells were plated into a 24-well tis­
sue culture plate, 1 mL of suspension 
per well. Both unstimulated and 
stimulated (with lipopolysaccharide 
[10 pg/mL| from Escherichia coli, se­
rotype 055:B5, Sigma Chemical Com­
pany) cytokine production was meas­
ured after a 24-hr incubation at 37°C 
(5% C02). Cytospin preparations of 
these cell suspensions were stained 
with Giemsa and May-Grunwald 
(Merck Diagnostica, Darmstadt, 
Germany).
Cytokine Assays. Plasma concentra­
tions of the cytokines IL-la, IL-1(3, 
TNF-a, and IL-6 , and the capacity of 
peritoneal macrophages to produce 
these cytokines were determined by 
assaying the plasma and supernatants 
of unstimulated and lipopolysaccha- 
ride-stimulated cultures. After incu­
bation of peritoneal cells, the super­
natants (for measuring IL-lp, TNF-a, 
and IL-6 ) and cells (for measuring cell 
associated IL- la) were collected 
seperately, aliquoted, and stored at 
-70°C until assay. Cells were frozen 
and thawed three times to release the 
cell-associated cytokine IL-la. IL-la, 
IL-1(3, and TNF-a were measured by 
specific radioimmunoassay (RIA). 
Standards, culture supernatants, cell 
lysates, and plasma samples were di­
luted in an RIA-buffer (60 mM 
Na2HP0,-2H20; 12 mM EDTA; 1 mL
sodium-azide [20%]; 2.5 g of bovine 
serum albumin [RIA-grade; Sigma 
Chemical); 1 mL triton X-100; 25 mL 
of aprotinin [Bayer, Leverkusen, Ger­
many] in 1 L of distilled water, pH of 
7.4). One hundred microliters of an 
appropriate rabbit anticytokine-anti- 
serum was added to 100 pL samples 
and standards and the tubes were kept 
on ice. After vortexing, the tubes were 
incubated for 24 hrs at 4°C. Subse­
quently, 100 pL of the appropriate 125I- 
labeled cytokine containing -10,000 
counts per minute were added to each 
tube, and incubation was continued 
for a further 24 hrs at 4°C. Then, 750 
pL of RIA buffer containing 9% (weight/ 
volume) polyethylene glycol 6000 
(Merck Diagnostica, Darmstadt, Ger­
many), and 3% (volume/volume) goat- 
antirabbit serum was added. The tubes 
were incubated for 20 mins at room 
temperature and then centrifugated 
at 1500 g for 15 mins. Supernatants 
were discarded carefully and quickly 
drained on absorbent paper. Remain­
ing radioactivity was counted in a y- 
counter. The radioactivity in control 
tubes (the nonspecific binding activ­
ity) was subtracted from samples and 
standards. Detection limits were be­
tween 0.05 and 0.10 ng/mL. IL-6 ac­
tivity was determined, using the B9 
hybridoma cell proliferation assay. B9 
cells were cultured at a density of 5 x 
103 cells/well in a microtiter plate, in 
200 pL of Iscove’s modified Dulbecco’s 
Medium (IMDM) (Gibco, Paisley, UK) 
supplemented with 40 pg/mL gentami­
cin sulfate and 10% heat inactivated 
fetal calf serum, in the presence of 
either serial dilutions of culture su­
pernatants or plasma. B9 cell prolif­
eration was measured by [3H]- 
Thymidin incorporation (Amersham, 
UK) during the last 18 hrs of the 72- 
hr incubation. The standard curve ob­
tained with human recombinant IL-6 
was used to determine the bioactivity 
of IL-6 in the culture supernatants 
and plasma samples. One unit of IL-6 
was the amount required to promote 
the half maximal growth of the B9 
cells. When plasma samples were de­
termined, 0.38% citrate was added to 
the culture medium to prevent clot­
ting. This citrate concentration had 
no influence on the assay.
Statistical Analysis. The Wilcoxon 
test was used to examine differences 
between cytokine production by cells 
from control and experimental groups.
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For such analyses, p < .05 was consid­
ered significant. The Mann-Whitney 
test was used to examine differences 
between the body weight, body tem­
perature, and organ weights of control 
and experimental groups. When this 
test was used, p < .05 was considered 
significant.
RESULTS
Intraperitoneal injection with zy­
mosan resulted in a three-phasic ill­
ness. During the first phase (days 0 to 
2 ), the injection caused an acute peri­
tonitis, rendering the animals very ill, 
as was apparent from weight loss, di­
arrhea, and lethargic behavior. Ap­
proximately 25% of the animals died 
during this phase. After 2 days, the 
animals seemed to recover, demon­
strated by a gain in body weight and 
vitality. None of the animals died in 
this second phase (days 3 to 7). Dur­
ing the third phase (days 8 to 12), 
which started 7 to 8 days after admin­
istration of zymosan, the animals be­
came ill again with weight loss, le­
thargic behavior, hypothermia, and 
dyspnea, suggesting the onset and de­
velopment of multiple organ dysfunc­
tion syndrome. Autopsy of animals on 
day 12 showed hemorrhagic lungs, en­
larged spleen and liver, and histo­
pathologic changes, further indications 
for multiple organ dysfunction syn­
drome. Figure 1 shows the changes in 
body temperature and weight during 
the three phases of the model, illus­
trating the course of the illness. Fur­
ther indications for organ damage or 
changes were the relative and abso­
lute organ weights (Fig. 2). There was 
a significantly (p < .05, Fig. 2A) in­
creased relative organ weight of liver, 
lung, and spleen. Also, the absolute 
organ weights (p < .05, Fig. 2B) of the 
lungs and spleen were significantly 
increased, while the absolute liver 
weight was not. Furthermore, there 
was a significant decrease in absolute 
kidney weight.
Circulating Cytokines. Within 3 hrs 
after injection with zymosan, increased 
circulating concentrations of TNF-a, 
as measured by RIA, were detected. 
These concentrations decreased to 
nondetectable values within 18 hrs 
(Fig. 3A). TNF-a was not detectable 
again until 8 days after zymosan ad­
ministration, when it started to in­
crease again and remained increased
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F igure  1 . Course of temperature (A) and 
body weight (B ) changes in a control group 
(circles) and a group that received intra­
peritoneal zymosan on day 0 (diamonds). 
Data are expressed as mean ± sem  (n =  11) .  
Significant (p < .05) difference between 
groups by Mann-Whitney test.
F igure  2. Both relative (A ) and absolute (Æ) 
wet organ weight in control animals (open 
bars) and in animals 12  days after intraperi­
toneal administration of zymosan (solid 
bars). The relative organ weight is calcu­
lated as: wet organ weight/total body weight 
x 100%. Data are expressed as mean ± sem  
(n = 1 1 ). Denotes significant (p < .05) differ­
ence between groups by Mann-Whitney test.
until the animals were killed. Analy­
sis of these samples with the L929 
bioassay for TNF showed that the first 
peak of immunoreactive TNF-a was 
also biologically active (5.8, 8.7, and 
2.0 ng/mL at 3, 6 , and 18 hrs after 
administration of zymosan, respec­
tively), while the second immunoreac­
tive TNF peak measured in the late 
phase was not (TNF was not detect­
able at 2, 5, 8 , 10, 11, and 12 days 
after administration of zymosan). Fig­
ure 3B shows the course of IL-6 con­
centrations in plasma: very high 
concentrations were found from 3 to 
18 hrs after zymosan injection. The 
concentrations decreased after 1 day, 
but remained -10 times higher than 
in the controls throughout the rest of
the experiment; concentrations did not 
increase when TNF increased again. 
IL-la concentrations in plasma (Fig. 
3C) were slightly above the values 
obtained in control animals (0.16 ng/ 
mL vs. 0.09 ng/mL, respectively) 3 hrs 
after zymosan administration, and 
there was also a slight but transient 
increase at the beginning of the late 
phase (0.17 ng/mL at day 7). Circulat­
ing IL-1 (3 was not detectable at any 
time.
Cytokine Production By Peritoneal 
Cells. Cytospin preparations at differ­
ent phases in the model showed that 
>95% of the peritoneal cells were 
macrophages.
Directly after zymosan injection, 
unstimulated TNF-a production (Fig.
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F igure  3. Circulating plasma concentrations of immunoreactive tumor necrosis factor 
(TNF-alpho.A), biologically active interleukin-6 (IL-6, B), and immunoreactive interleukin- 
1 alpha (IL-1 alpha, C ) in a group of control (C) mice and in groups of animals at various 
time points after intraperitoneal administration of zymosan. At each time point, two 
plasma pools from seven animals each were analyzed and the values represent the mean 
values from the two pools, nd, not detectable.
4) was significantly suppressed com­
pared with production by cells derived 
from control animals. Within 8 hrs, 
the unstimulated production of TNF 
was back to control values. There was 
a significant, two-fold increase on day 
3 (0.67 vs. 0.36 ng/mL in control, p < 
.05) in production of TNF compared 
with control. After that, the values 
remained significantly increased in 
this phase, except on day 5. From day 
7 onward, the production decreased to 
control values, and at day 12 the TNF 
production was significantly decreased 
(0.17 vs. 0.36 ng/mL in control, p < .05).
Lipopolysaccharide-stimulated pro­
duction of TNF-a was also suppressed 
initially but increased significantly
within 18 hrs after administration of 
zymosan (1.56 vs. 0.93 ng/mL in con­
trol, p < .05; Fig. 4). Toward the end of 
the second phase, there was a four­
fold increase in stimulated TNF pro­
duction (4.09 ng/mL on day 6 vs. 0.93 
ng/mL in control, p < .001). At the end 
of this phase and at the beginning of 
the third phase, there was a transient 
decrease. However, at all times the 
concentrations remained significantly 
increased above those concentrations 
measured in control animals (e.g., 1.27 
ng/mL on day 9 vs. 0.93 ng/mL in the 
control group, p < .05). Thereafter, the 
production increased further.
The unstimulated production of IL-
6 was significantly suppressed at all
phases when compared with control 
values (p < .01 at all times, Fig. 4). 
Lipopolysaccharide-stimulated IL-6 
production was significantly sup­
pressed in the first phase, but in the 
second and third phase this produc­
tion was similar to control values.
Figure 5 shows that unstimulated 
production of IL-la was significantly 
suppressed (p < .001 at all times) 
throughout the experiment, except at
6 , 7, and 8 days after administration 
of zymosan. Lipopolysaccharide-stimu­
lated production of IL-la was sup­
pressed significantly at all time points 
in both the first and the second phase 
(p < .001 and p < .05, respectively). At 
the end of the second phase and in the 
third phase (from day 7 onward), the 
production levels were again similar 
to control.
Unstimulated production of IL-1 [3 
was transiently but significantly sup­
pressed directly after administration 
of zymosan (Fig. 5). During the sec­
ond phase (days 3 to 7) the production 
was also suppressed significantly (p < 
.0 1 ). However, it increased to control 
values at the beginning of the third 
phase. Lipopolysaccharide-stimulated 
production of IL-1 [3 was significantly 
suppressed the first 6 hrs when com­
pared with control values. Thereafter, 
it increased significantly (p < .05 at 
all time points from day 2 onward) 
and remained increased throughout 
the rest of the experiment.
%
DISCUSSION
Zymosan-induced generalized in­
flammation in the mouse clearly re­
sults in a triphasic illness. These three 
phases differ not only in terms of de­
gree of illness but also in cytokine 
patterns.
In the first phase of the model, 
which reflects the shock state, circu­
lating TNF peaks immediately after 
zymosan administration. This TNF 
peak is followed by an increase in cir­
culating IL-6 concentrations. Produc­
tion of TNF by peritoneal macrophages 
(stimulated as well as unstimulated) 
is significantly suppressed at this time, 
as is the production of IL-6 . IL-1 f3 is 
not detectable in the circulation, 
whereas IL-la is detectable. The find­
ing of detectable circulating IL-la and 
nondetectable IL-1(3 seems to be dif­
ferent from the situation in humans, 
where IL-1 (3 is the major cytokine
Crit Care Med 1996 Vol. 24, No. 7 1199
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F igure  4. Top: Tumor necrosis factor (TNF-alpha) production by peritoneal macrophages. 
Bottom: Interleukin-6 (IL-6) production by peritoneal macrophages. Comparison of lipo- 
polysaccharide-stimulated (open bars) and nonstimulated (solid bars) in vitro release of 
immunoreactive TNF-alpha (top), and biologically active IL -6 (bottom) by mouse peritoneal 
cells, harvested at different time points after intraperitoneal administration of zymosan 
and by cells derived from control (C) animals. Values represent the median from observa­
tions on individual cultures from eight to 14 mice.
released and IL-la is largely cell- 
associated. The absence of IL-1 (3 in 
the circulation does not imply that 
there is no increase in production in 
the tissues. The fact that the produc­
tion capacity for IL-1(3 by peritoneal 
cells is largely preserved during the 
first phase, could be taken as support 
for such a suggestion.
The cytokine patterns that we ob­
serve during the first phase partly 
agree with findings of Ayala and col­
leagues (25, 26), who found a marked 
spontaneous release of IL-1, IL-6 , and 
TNF-a 1 hr after cecal ligation and 
puncture (CLP). Addition of endotoxin 
to peritoneal macrophage cultures 
from CLP mice had no further stimu­
latory effect. In the zymosan-induced 
generalized inflammation model, the 
unstimulated and stimulated IL-la 
and IL-6 production is suppressed 3 
hrs after zymosan administration. IL- 
1(3 and TNF-a production in our model 
is virtually unchanged during the first 
24 hrs after zymosan administration.
This result is in contrast with the find­
ings of Ayala et al. (26), who found 
that only TNF-a remained unaltered 
4 hrs and 24 hrs after CLP. In the 
CLP model, the blunting of lipopolysac- 
charide-inducible cytokine production 
probably represents the development 
of a kind of tolerance phenomenon as 
is also seen during sepsis (27). Our 
study shows a more disparate cytokine 
response.
During the second phase, there is 
no TNF-a detectable in the circula­
tion, while IL-6 concentrations are 
supranormal. Stimulated and un­
stimulated production of TNF-a is sig­
nificantly increased when compared 
with production of cells collected from 
control animals during this phase. The 
conditions of the macrophages that 
produce these cytokines in vitro are 
not necessarily the same as in vivo, 
but the in vitro conditions represent 
at least two extreme situations (with 
or without triggering agent) that could 
occur within the peritoneal cavity. The
total number of cells in the peritoneal 
cavity 2 days after zymosan adminis­
tration is ten times higher than in 
control animals. This increase in cell 
number means that there is an enor­
mous production capacity for TNF-a 
in the peritoneal cavity. Stein and 
Gordon (28) found that zymosan ad­
ministration results in a prolonged re­
lease of TNF, suggesting that the unde­
graded intracellular zymosan particles 
cause ongoing release of TNF. Such 
phenomenon could also happen in vivo, 
when zymosan is present, although 
there is no TNF-a detectable in the 
circulation. Apparently, the animals 
can handle the excessive TNF-a pro­
duction capacity during this phase.
IL-6 production by peritoneal cells 
in this phase is significantly decreased 
(unstimulated) or similar to normal 
(stimulated). Considering again the 
ten-fold increase in cells in the perito­
neal cavity, it seems possible that the 
slightly increased concentrations found 
in the circulation merely reflect this 
increased number of cells.
Circulating IL-la concentrations 
are increased at the end of the second 
phase, while unstimulated as well as 
stimulated production by peritoneal 
cells is normal at the end of this phase. 
As for IL-6 , the increased cell number 
could be responsible for the increase 
found in the circulation.
Unstimulated production of IL-1 (3 
is significantly reduced. However, con­
sidering the cell number in the perito­
neal cavity, the total production ca­
pacity could be much higher than in 
controls. Stimulated IL-1(3 production 
is significantly increased. However, 
circulating concentrations are neither 
found in these animals, nor in control 
animals. As in the first phase, the 
activity of IL-1(3 seems to be confined 
to the local inflammatory process. The 
suggestion that the cells develop a kind 
of tolerance (25) is also not true in this 
phase of the model.
During the most interesting phase, 
the third phase, the animals develop 
the multiple organ dysfunction syn­
drome. Immunoreactive TNF-a con­
centrations in the circulation increase 
again, while the unstimulated produc­
tion by peritoneal cells decreases be­
low control values and stimulated pro­
duction increases significantly above 
control.
IL-6 does not increase to high con­
centrations again in the circulation
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F igure  5. Interleukin-1 alpha (IL-l alpha; top) and interleukin-1 beta (IL-l beta) produc­
tion by peritoneal macrophages. Comparison of lipopolysaccharide-stimulated (open bars) 
and nonstimulated (solid bars) in vitro release of immunoreactive IL-l alpha and IL-l beta 
by mouse peritoneal cells, harvested at different time points after intraperitoneal adminis­
tration of zymosan and by cells derived from control (C) animals. Values represent the 
median from observations on individual cultures from eight to 14 mice.
but remains at a slightly increased 
concentration, whereas unstimulated 
production stays significantly reduced 
when compared with control values. 
The TNF-a peak in this phase is not 
followed by an IL-6 peak as is usually 
seen. However, it appears that the 
immunoreactive TNF-a found in the 
circulation at this time was largely 
biologically inactive, possibly because 
of the presence of circulating soluble 
receptors.
There is considerable lung damage 
that can be seen macroscopically (hem­
orrhages, edema) and which is appar­
ent from the breathing difficulties of 
the animals. Also, there are foci of 
inflammation in the liver. Cytokines 
such as TNF, acting at the tissue level, 
are responsible for these abnormali­
ties and thus contribute to the onset 
and development of multiple organ 
dysfunction syndrome, as suggested 
by others (20 , 2 1 ) on the basis of data 
from patient studies.
We do not know to what extent 
cytokines produced by peritoneal cells
contribute to the circulating concen­
trations and to remote tissue damage. 
Considering that numbers of cells in 
the peritoneal cavity are similar to 
control animals during this phase, 
other populations of cells probably con­
tribute to the slightly increased con­
centrations in the circulation. Further 
studies are being conducted to eluci­
date this issue.
Circulating IL-1 (3 concentrations 
are not detectable, while stimulated 
production is significantly increased 
and unstimulated production by peri­
toneal cells is virtually normal. Ap­
parently, IL-1[3 is restricted to the cel­
lular level or scavenged by other 
proteins.
Circulating IL-la concentrations 
are similar to control values, whereas 
unstimulated production is signifi­
cantly suppressed and stimulated pro­
duction is similar to control values. 
These data could imply that the IL-la 
found in the circulation is generated 
at a site other than the peritoneal 
cavity.
he present study 
shows a complex 
pattern of circu­
lating cytokines and produc­
tion of these cytokines by 
peritoneal macrophages  
during  the subsequent  
phases after zym osan  
administration.
There are various possibilities re­
garding the contribution of peritoneal 
cells to circulating cytokine concen­
trations. It is possible that the cells 
are in a continuously activated state, 
due to the persisting zymosan stimu­
lation. The fact that unstimulated pro­
duction of all four cytokines is similar 
to normal or even below normal dur­
ing the third phase does not necessar­
ily contradict the role of zymosan as a 
continuous stimulus, because the pro­
duction is measured in vitro under 
circumstances different from those 
present in vivo (29). This fact makes 
it difficult to predict what is actually 
happening in the peritoneal cavity dur­
ing different phases in the zymosan- 
induced generalized inflammation 
model.
The present study shows a complex 
pattern of circulating cytokines and 
production of these cytokines by peri­
toneal macrophages during the subse­
quent phases after zymosan adminis­
tration. The peritoneal macrophage is 
altered in its capacity to produce 
cytokines after being in contact with 
zymosan when compared with the nor­
mal situation. There seem to be differ­
ential changes in stimulated as well 
as unstimulated production of the four 
cytokines studied here, but it seems a 
differentiated continuous response. 
Furthermore, the changes in circulat­
ing cytokines differ in each phase of 
the model. The contribution of other 
macrophage populations to these 
changes needs to be elucidated. In the 
third phase, when there are foci of 
inflammation in liver and lungs, the 
macrophage populations in these tis­
sues are likely to be altered in their 
function as well. If these macrophages
Crit Care Med 1996 Vol. 24, No. 7 1201
are triggered to produce cytokines, 
they too could contribute to the 
spillover found in the circulation. The 
TNF-a peak found in this phase is 
biologically inactive, but the supra- 
normal biologically active IL-6 concen­
trations are not inactivated or cleared. 
This inactivation and differential 
clearing may possibly contribute to, 
or be a result of, insufficient regula­
tion of the immune response and may 
thus lead to multiple organ dysfunc­
tion syndrome.
These findings seem to confirm our 
hypothesis that the macrophages are 
in a continuously activated state, and 
altered in their function, when the ani­
mals develop multiple organ dysfunc­
tion syndrome. Further studies are 
needed to elucidate what happens with 
these cytokines at the tissue level, to 
better understand the pathophysiol­
ogy of multiple organ dysfunction 
syndrome.
ACKNOWLEDGMENTS
We thank Karin M. L. C. Huijben, 
Leo M. G. Geeraedts, Jr, and Ineke 
Verschueren for their expert technical 
contributions.
REFERENCES
1 . Members of the American College of 
Chest physicians/Society of Critical Care 
Medicine Consensus Conference Com­
mittee: Definitions for sepsis and organ 
failure and guidelines for the use of in­
novative therapies in sepsis. Crit Care 
Med 1992; 20:864-874
2. Faist EA, Baue E, Dittmer H, et al: 
Multiple organ failure in poly-trauma 
patients. J  Trauma 1983;23:775-787
3. Marshall WG, Dimick AR: Natural his­
tory of major burns with multiple sub­
system failure. J  Trauma 1983; 23:
102-105
4. Saffle JR , Sullivan J J , Tuohig GM, et al: 
Multiple organ failure in patients with
thermal injury. Crit. Care Med 1993; 21: 
1673-1683
5. Aikowa N, Shinozawa Y, Ishibiki K: 
Clinical analysis of Multiple Organ Fail­
ure in burned patients. Burns 1987; 13:
103-109
6 . Allardyce DB: Incidence of necrotizing 
pancreatitis and factors related to mor­
tality. Am J  Surg 1987; 154:295-299
7. Baue AE, Guthrie D: Multiple system 
failure and circulatory support. Jpn J  
Surg 1983; 13:69-85
8 . Deitch EA: Multiple organ failure. Ann 
Surg 1992; 216:117-134
9. Goris RJA, Boekholtz WKF, van Bebber 
IPT, et al: Multiple organ failure and 
sepsis without bacteria. Arch Surg 1986; 
121:897-901
10. Auger MJ: Mononuclear phagocytes. 
BMJ 1989; 298:546-548
11. Johnston Jr  RB: Monocytes and macro­
phages. N Engl J  Med 1988; 318: 
747-752
12. Nathan CF: Secretory products of mac­
rophages. J  Clin Invest 1987; 79:319-326
13. Le J, Vilcek J: Biology of disease. Tu­
mor necrosis factor and interleukin 1 : 
Cytokines with multiple overlapping bio­
logical activities. Lab Invest 1987; 56: 
234-248
14. Nerad JL , Griffiths JK , van der Meer 
JW M , et al: Interleukin-1(3 (IL-1(3), IL-1 
receptor antagonist, and TNF-a produc­
tion in whole blood. J  Leuk Biol 1992; 
52:687-691
15. Calandra T, Gerain J, Baumgartner JD , 
et al: H igh c ircu la ting  levels of 
interleukin-6 in patients with septic 
shock: Evolution during sepsis, prog­
nostic value, and interplay with other 
cytokines. Am J  Med 1991; 91:23-29
16. Goris RJA: Mediators of multiple organ 
failure. Intensive Care Med 1990; 16: 
192-196
17. Goris RJA, te Boekhorst TPA, Nuytinck 
JKS, et al: Multiple Organ Failure. Gen­
eralized autodestructive inflammation? 
Arch Surg 1985; 120:1109-1115
18. Roumen RMH, Hendriks T, van der Ven- 
Jongekrijg J, et al: Cytokine patterns 
in patients after major vascular surgery, 
haemorrhagic shock and severe blunt 
trauma: Relation with subsequent 
ARDS and MOF. Ann Surg 1993; 218: 
769-776
19. Nuytinck JKS, Offermans XJM , Kubat 
K, et al: Whole-body inflammation in 
trauma patients. Arch Surg 1988; 123: 
1519-1524
20. Tracey KJ, Cerami A: Tumor necrosis 
factor: An updated review of its biol­
ogy. Crit Care Med 1993; 21:S415-S422
21. Beutler B, Grau GE: Tumor necrosis 
factor in the pathogenesis of infectious 
diseases. Crit Care Med 1993; 21: 
S423-S435
22. Steinberg S, Flynn W, Kelley K, et al: 
Development of a bacteria-independent 
model of the multiple organ failure syn­
drome. Arch Surg 1989; 124:1390-1395
23. Deitch EA, Abbie C, Kemper BS, et al: 
A study of the relationships among sur­
vival, gut-origin sepsis, and bacterial 
translocation in a model of systemic in­
flammation. J  Trauma 1992; 32: 
141-147
24. Bebber van IPT, Lieners CFJ, Koldewijn 
EL, et al: Superoxide dismutase and 
catalase in an experimental model of 
multiple organ failure. J  Surg Res 1992; 
52:265-270
25. Ayala A, Kisala JM , Felt JA, et al: Does 
endotoxin tolerance prevent the release 
of inflammatory cytokines (interleukin
1 , interleukin 6 , or tumor necrosis fac­
tor) during sepsis. Arch Surg 1992; 127: 
191-197
26. Ayala A, Perrin MM, Kisala JM , et al: 
Polymicrobial sepsis selectively activates 
peritoneal but not alveolar macrophages 
to release in flam m atory  mediators 
(interleukin-1 , and -6 and tumor necro­
sis factor). Circ Shock 1992;36:191-199
27. Deuren van M, van der Ven-Jongekrijg 
J, Demacker PNM, et al: Differential 
expression of proinflammatory cytokines 
and their inhibitors during the course of 
meningococcal infections. J  Infect Dis 
1994;169:157-161
28. Stein M, Gordon S: Regulation of tu ­
mor necrosis factor (TNF) release by 
murine peritoneal macrophages: Role 
of cell stimulation and specific phago­
cytic plasma membrane receptors. Eur 
J  Immunol 1991; 21:431-437
29. Wollenberg GK, DeForge LE, Bolgos G, 
et al: Differential expression of tumor 
necrosis factor and interleukin 6 by peri­
toneal macrophages in vivo and in cul­
ture. J  Pathol 1993; 143:1121-1130
1202 Crit Care Med 1996 Vol. 24, No. 7
